[Clinical development of antitumoral vaccines] (Q77957289)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11958766%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

review article

1 reference

title

[Clinical development of antitumoral vaccines] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11958766%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

author name string

Antoni Ribas

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11958766%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

Manuel Ribas-Mundó

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11958766%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

publication date

1 April 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11958766%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11958766%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

volume

118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11958766%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11958766%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

page(s)

472-476

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11958766%20AND%20SRC:MED&resulttype=core&format=json

Tolerance, danger, and the extended family

9 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

[Antitumor immunology in the year 2000 and the new immunosuppressive therapy]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Immunotherapy of human solid tumors with Bacillus Calmette-Guérin: prolongation of disease-free interval and survival in malignant melanoma, breast, and colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Unresponsiveness to a self-peptide of mouse lysozyme owing to hindrance of T cell receptor-major histocompatibility complex/peptide interaction caused by flanking epitopic residues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Genetic vaccination: the advantages of going naked

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Genetic immunotherapy for cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Phase I study of recombinant human CD40 ligand in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Carbohydrate antigens as targets for active specific immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972421-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-7753(02)72421-4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11958766%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

1 reference